{"id":51236,"date":"2022-11-24T18:02:11","date_gmt":"2022-11-24T17:02:11","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-metagenomics-shotgun-sequencing-16s-sequencing-market-size-share-trends-analysis-report-2022-2030-researchandmarkets-com\/"},"modified":"2022-11-24T18:02:11","modified_gmt":"2022-11-24T17:02:11","slug":"global-metagenomics-shotgun-sequencing-16s-sequencing-market-size-share-trends-analysis-report-2022-2030-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-metagenomics-shotgun-sequencing-16s-sequencing-market-size-share-trends-analysis-report-2022-2030-researchandmarkets-com\/","title":{"rendered":"Global Metagenomics (Shotgun Sequencing, 16S Sequencing) Market Size, Share & Trends Analysis Report 2022-2030 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Metagenomics Market Size, Share & Trends Analysis Report by Technology (Shotgun Sequencing, 16S Sequencing), by Product, by Workflow, by Application (Clinical Diagnostics, Environmental), by Region, and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global metagenomics market size is expected to reach USD 4.87 billion by 2030. The market is projected to expand at a CAGR of 14.4% from 2022 to 2030\n<\/p>\n

\nThe increasing research in genomics and proteomics, the rising adoption of personalized medicines, and escalating requirement for biologic products are driving the demand for sequencing, fueling the growth of the industry.\n<\/p>\n

\nFor instance, in August 2022, Illumina, Inc. announced its plans to expand genomics operations in Brazil by developing a solution center. The establishment of the new facility is the result of rising demand for clinical genomics and accelerating the company’s footprint in Latin America.\n<\/p>\n

\nA boost in R&D investments by the players is estimated to have a considerable impact on the usage of metagenomics in numerous applications. For instance, in April 2021, Agilent Technologies, Inc. acquired Resolution Bioscience, Inc., an NGS-based precision oncology solution developing company.\n<\/p>\n

\nThe combination of Resolution Bioscience’s noninvasive liquid biopsy platform with Agilent’s tissue-based companion diagnostics is anticipated to expand Agilent’s market position in NGS technologies for precision oncology.\n<\/p>\n

\nAnother factor contributing to the high adoption of metagenomics for environmental use is the direct involvement of microorganisms in the biogeochemical cycle. The degradation of carbon sources such as petroleum hydrocarbons by microbes has encouraged researchers to study metagenomics processes for the production of biofuels.\n<\/p>\n

\nIn addition, the presence of a large number of undiscovered biomolecules in non-cultured microorganisms accelerated the adoption of metagenomics in agriculture, food safety, chemical, industrial, and other related applications.\n<\/p>\n

\nSince the outbreak of COVID-19, key stakeholders in the life sciences and biotechnology industry are seeking solutions for COVID-19 tracking, detection, and treatment. Metagenomics analysis plays a crucial role in the detection and tracing of the virus. Various sequencing surveillance platforms and solutions are being deployed for effective diagnosis of infection.\n<\/p>\n

\nFor instance, in May 2021, Oxford University and Oracle announced a strategic partnership to develop robust cloud-based genomic sequencing and analysis platform to mitigate the risk of coronavirus infection.\n<\/p>\n

\nMoreover, funds provided by the government for promoting research in academic institutes, which use NGS platforms, further increase the usage of metagenomics tools. For instance, in February 2021, the Canadian government invested USD 53 million to implement a multilayered approach for the diagnosis of COVID-19. The Canadian government will utilize genome sequencing and analysis technologies to achieve desired outcomes.\n<\/p>\n

\nThe quality of data generated through metagenomics is another factor that increases the cost of analysis. The quality of data is highly dependent on the average number of times the bases are run during the sequencing process. The high-quality analysis is expensive.\n<\/p>\n

\nHowever, the adoption of emerging novel techniques, such as RNA-Seq, is rapidly increasing owing to accuracy and rapid results along with a decline in prices. It is observed that the cost of sequencing falls 5 to 10 times every year and the value of computing power doubles every two years.\n<\/p>\n

\nMetagenomics Market Report Highlights<\/strong>\n<\/p>\n